Research programme: oncolytic viruses - Transgene

Drug Profile

Research programme: oncolytic viruses - Transgene

Alternative Names: anti-PD-1 immune checkpoint inhibitor - Transgene; J43-armed-Western Reserve oncolytic vaccinia virus; TG 6002; VV-TK-RR-FCU1

Latest Information Update: 28 Nov 2016

Price : $50

At a glance

  • Originator Transgene
  • Class Immunotherapies; Oncolytic viruses
  • Mechanism of Action Checkpoint kinase inhibitors; Immunomodulators; Prodrug activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 05 Sep 2016 Preclinical development is ongoing France
  • 01 Apr 2016 Interim data from preclinical study in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR - 2016)
  • 08 Mar 2016 Transgene plans a phase I trial in Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top